ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

NCT01779206 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

4936

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Epirubicin
DRUG: Cyclophosphamide
DRUG: Docetaxel
DRUG: Paclitaxel

Sponsor

West German Study Group